Search This Blog

Monday, September 30, 2019

Servier acquires lymphoma treatment PIXUVRI from CTI BioPharma

Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.
“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”
https://www.marketscreener.com/news/Servier-acquires-non-Hodgkin-B-cell-lymphoma-treatment-PIXUVRI-pixantrone-from-CTI-BioPharma-s–29317108/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.